AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Epizyme Announces Presentations at Upcoming March Investor Conferences

March 5, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 5, 2019--Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March investor conferences:

  • Cowen 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:20 a.m. ET in Boston; and,
  • Oppenheimer & Co. 29 th Annual Healthcare Conference at 11:00 a.m. ET on March 20, 2019 in New York City.

Live webcasts will be available in the investor section of the company’s website at  www.epizyme.com. The webcasts also will be archived for 60 days following the call and presentation.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme’s science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190305005160/en/

CONTACT: Media:

Erin Graves, (617) 500-0615

Epizyme, Inc.

media@epizyme.comInvestors:

Monique Allaire, (617) 896-9511

THRUST Strategic Communications

monique@thrustsc.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Epizyme, Inc.

Copyright Business Wire 2019.

PUB: 03/05/2019 06:30 AM/DISC: 03/05/2019 06:30 AM

http://www.businesswire.com/news/home/20190305005160/en